Filing Flows › Celldex Therapeutics (CLDX) › Q1 2025
Celldex Therapeutics (CLDX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Celldex Therapeutics (CLDX) reported revenue of $695K for the first quarter 2025 (Q1 2025), +346% from a year earlier and -41% from the quarter before.
Celldex Therapeutics, Q1 2025: revenue $695K (+346% year over year), net loss $53.8M, operating cash flow −$54.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $695K | -41% | +346% |
| Operating profit | −$62.7M | — | — |
| Net earnings | −$53.8M | — | — |
| Operating cash flow | −$54.4M | — | — |
What changed
Revenue was $695K in Q1 2025, up 346% year over year and down 41% from the previous quarter. Contracts and grants was the largest line at 93% of revenue. Contracts and grants added $491K year over year (up 319%), 91% of the total change.
Operating costs exceeded revenue by $62.7M, an operating margin of -9027.2%. Total costs grew 56% against revenue growth of 346%. The fastest-growing cost line was Research & development (+66%). The quarter ended with a net loss of $53.8M, wider than the previous quarter's $47.1M loss.
Operating cash flow was −$54.4M. Non-cash charges added back $867K of depreciation and amortization and $9.3M of share-based compensation. Working capital and other items used $10.8M. Capital expenditures of $265K exceeded it, leaving free cash flow of −$54.6M.
Questions
What was Celldex Therapeutics' revenue in the first quarter 2025?
Celldex Therapeutics (CLDX) reported revenue of $695K for the first quarter 2025 (Q1 2025), +346% from a year earlier and -41% from the quarter before.